Profile: Sunesis Pharmaceuticals Inc (SNSS.O)
26 May 2017
Sunesis Pharmaceuticals, Inc., incorporated on February 10, 1998, is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZOTM (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative (AQD). The Company's other kinase inhibitor pipeline include TAK-580, SNS-062 and SNS-229.
Vosaroxin is an AQD, which is used for the treatment of cancer. The Company has completed a Phase III clinical trial of Vosaroxin for relapsed/refractory AML. The Company is engaged in conducting Phase II clinical trials of Vosaroxin for frontline AML and myelodysplastic syndrome (MDS). The Company has also conducted two Phase II trials in non-small cell lung cancer and small cell lung cancer. The Company is focused on investing in the development and clinical testing of Vosaroxin for related disease areas and indications, such as other AML populations, MDS, other hematologic malignancies and solid tumors.
TAK-580 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. The Phase I, multicenter, open-label and dose escalation study was conducted in two stages: dose escalation and cohort expansion. The Company has completed the dose escalation study for TAK-580 and TAK-580 is in the cohort expansion stage of this multicenter study.
SNS-062 is a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK). BTK mediates signaling through the B-cell receptor (BCR), which is critical for adhesion, migration, proliferation and survival of normal and malignant B-lineage lymphoid cells. The Company has completed the pre-clinical studies for SNS-062. SNS-062 demonstrated a binding site and pharmacokinetic profile in preclinical studies. It may provide opportunities for treatment of B-cell malignancies and other blood cancers.
SNS-229 and SNS-510
SNS-229 and SNS-510 are two PDK1 inhibitors. PDK1 is a kinase and mediator of Phosphoinositide 3-kinase/AKT (PI3K/AKT) signaling, which is a pathway involved in cell growth, differentiation, survival and migration. PDK1 inhibitors have effects on survival and invasion signaling and are active in both hematologic and solid tumor malignancies. The Company has taken a series of PDK1 inhibitors with antitumor activity in vitro and in vivo into preclinical development. PDK1 inhibitors are in research and development, and may provide opportunities for treatment of solid and hematological malignancies.
Sunesis Pharmaceuticals Inc
395 Oyster Point Blvd Ste 400
SOUTH SAN FRANCISCO CA 94080-1995
Company Web Links
- BRIEF-Sunesis Pharmaceuticals qtrly basic and diluted loss per share $0.47
- BRIEF-Sunesis Pharma announces withdrawal of European MAA for vosaroxin
- BRIEF-Aimmune Therapeutics appoints Eric Bjerkholt as CFO
- BRIEF-Sunesis Pharmaceuticals says CFO Eric Bjerkholt to resign to pursue another opportunity - SEC Filing
- BRIEF-Sunesis Pharmaceuticals reports presentation of preclinical study of btk inhibitor sns-062